Sight Sciences to present GEMINI trial data at ASCRS

Sight Sciences “announced that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System and the TearCare System, will be presented in two oral presentations and two posters at this year’s ASCRS Annual meeting April 5th to 8th in Boston, MA. OMNI technology facilitates surgeons’ ability to perform a comprehensive, implant-free, minimally invasive glaucoma surgical procedure in adults with primary open-angle glaucoma. TearCare technology enables a proprietary, interventional eyelid procedure for diseased meibomian glands and is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease, or DED, due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands.” Paul Badawi, CEO and co-founder of Sight Sciences stated: “In addition to our existing robust body of clinical evidence, we now have additional data showing impressive OMNI results at 36-months, which demonstrate the vital long-term element of OMNI’s efficacy. We are also pleased that new TearCare data will be shared that supports the use of TearCare technology as a primary treatment for DED.”